Synthesis and antimalarial activity evaluation of 3-(3-(7-chloroquinolin-4-ylamino)propyl)-1,3-thiazinan-4-one derivatives

Mukesh Kumar Kumawat a,*, Udaya Pratap Singh b, Bhupendra Singh c, Anil Prakash d, Dipak Chetia e

a Anand College of Pharmacy, Keetham, Agra, Uttar Pradesh 282 007, India
b Department of Pharmaceutical Sciences, Allahabad Agricultural Institute-Deemed University, Allahabad, Uttar Pradesh 211007, India
c Department of Pharmacy, S.N. Medical College, Agra, Uttar Pradesh 282 002, India
d Regional Medical Research Centre (R.M.R.C.), I.C.M.R., N.E. Region, Dibrugarh, Assam 786 004, India
e Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam 786 004, India

Received 28 April 2011; accepted 11 July 2011

KEYWORDS
7-Chloro-4-aminoquinoline; Antimalarial activity; In vitro; Plasmodium falciparum

Abstract Some novel derivatives of 3-(3-(7-chloroquinolin-4-ylamino)propyl)-1,3-thiazinan-4-one were synthesized and characterized by their physical and spectral data. All the synthesized compounds were subsequently screened for in vitro antimalarial activity against chloroquine sensitive strain of Plasmodium falciparum (RKL-2) employing chloroquine as the reference drug. Most of the synthesized compounds exhibited mild to moderate susceptibilities towards the parasite in comparison to the standard. It was found that antimalarial activity of 3-(3-(7-chloroquinolin-4-ylamino)propyl)-2-(4-bromophenyl)-1,3-thiazinan-4-one was marginally superior than all the compounds evaluated.

© 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.

1. Introduction

Malaria is a life-threatening parasitic disease caused by protozoan parasites of the genus Plasmodium. Four species of the Plasmodium viz. P. falciparum, P. vivax, P. malariae, and P. ovale are responsible for the bulk of human malaria cases globally (http://www.rbm.who.int/) and more recently another species P. knowlesi infecting humans has been documented (White, 2008; WHO, 2007). P. falciparum is the most widespread, and causes most severe and potentially fatal malaria (Talisuna et al., 2004). Over the years chloroquine (CQ) has remained the drug of choice for the malaria chemotherapy,
because it is effective, less toxic and a cheap drug. The rapid spread of resistance of *P. falciparum* towards chloroquine and other available drugs has become a major health concern in the tropical and subtropical regions of the world (Sharma, 2007). Therefore, development of novel and effective antimalarial drug is the better approach to circumvent the problem faced by clinically used drugs.

The structure–activity relationship studies on 4-aminoquinoline antimalarial compounds suggested that the 7-chloro-4-aminoquinoline nucleus is obligatory for antimalarial activity, particularly, inhibition of β-haematin formation and accumulation of the drug at the target site (Werbel, 1986; Pandey et al., 2001; Chou et al., 1980). Shortening (2–3 carbon atoms) and lengthening (10–12 carbon atoms) of the carbon side chain in chloroquine (Fig. 1) leads to compounds that remain active against chloroquine-resistant strains of *P. falciparum* (Pandey et al., 2001; De et al., 1998; Solomon et al., 2005; Warhurst, 1981). Solomon et al. (2007) reported a new series of side-chain modified 4-aminoquinolines which was found active against *P. falciparum* (in vitro) and *P. yoelli* (in vivo). They also reported that the basicity of the side chain nitrogen is not very essential for antiplasmodial activity of 4-aminoquinoline, and the derivative having [1,3]-thiazinan-4-one ring system with 4-chlorophenyl substitution at the C-2 position attached to the terminal side chain amino group of 7-chloro-4-aminoquinoline was 8-fold more potent in antiplasmodial activity as compared to chloroquine.

These findings have given impetus to the concept that side chain modification is an attractive strategy for the development of antimalarial drugs with desirable bioactivity. Encouraged by these evidences, we presumed that selectively modifying the pendant amino group with small heterocyclic systems could modulate the antimalarial activity. Based on this, title analogues were designed wherein, 7-chloro-4-aminoquinoline fragment kept rigid and modifications were made at the C-2 position of a six membered [1,3] thiazinan-4-one ring attached at the terminal propyl side chain of 7-chloro-4-aminoquinoline. Accordingly, seven title molecules of 3-(3-(7-chloroquinolin-4-ylamino)propyl)-2-substituted 1,3-thiazinan-4-one were synthesized and subsequently screened for their in vitro antimalarial activity against laboratory cultured *P. falciparum*.

2. Materials and methods

2.1. Structural investigation

All chemicals used in the work were procured either from Sigma–Aldrich Corporation, USA or Merck Specialties Pvt. Ltd., Mumbai and were used without further purification. The intermediate was taken in an open capillary on the Veego-MPI melting point apparatus and the melting point of the synthesized compound was calculated. The progress of the reactions was monitored on silica gel-G TLC plate using various solvent combinations. The spots were detected with iodine vapours and illuminated under UV-light. The UV–visible spectra (λmax) of the synthesized compounds were recorded on UV–visible spectrophotometer (Shimadzu UV-1700). Infrared spectra were recorded on an FT-IR Perkin-Elmer spectrometer. The 1H and 13C NMR spectra were recorded at 400 MHz and 100 MHz, respectively on an Avance- 400 Bruker FT-NMR spectrometer using either DMSO-d6 or CDCl3 as solvent with tetramethylsilane (TMS) as an internal standard. Mass spectra were obtained on TOFMS+.

2.2. Antimalarial activity evaluation

All the synthesized compounds were evaluated for in vitro antimalarial activity against chloroquine sensitive strain (RKL-2) of *P. falciparum* (Pf) using 96 well-microtitre plates. The laboratory adapted strain of Pf was routinely cultured at 37 °C temperature and 5% CO2 environment in RPMI 1640 medium supplemented with 25 mM HEPES, 1% d-glucose, 0.23% sodium bicarbonate and 10% heat inactivated human serum (Trager and Jensen, 1976). For antimalarial testing the asynchronous parasites of Pf were synchronized to obtain only the ring stage parasitized cells by 5% α-sorbitol treatment. For carrying out the assay, the initial ring stage parasitemia of 0.8–1.5% at 3% haematocrit in a total volume of 200 μL of medium RPMI-1640 was uniformly maintained. A stock solution of 5 mg/ml was prepared by dissolving the test compounds in DMSO and subsequent dilutions were made with the culture medium. Twenty microlitres of the test compounds at 30 μg/ml concentrations in duplicate wells was incubated with parasitized cell preparation at 37 °C and 5% CO2 in a CO2 incubator. After an incubation period of 36–40 h, the blood smears were prepared from each well and stained with 3% Giemsa stain. The slides were microscopically observed and the percent dead rings and schizonts were scored against 100 asexual parasites with respect to the control group. Chloroquine was used as the standard reference drug.

3. Results and discussion

In the present study, seven new 3-(3-(7-chloroquinolin-4-ylamino)propyl)-1,3-thiazinan-4-one derivatives were synthesized and their antimalarial activity was evaluated in vitro against chloroquine sensitive *P. falciparum*.

The target compounds were prepared as outlined in Schemes 1 and 2. The N1-(7-chloroquinolin-4-yl)propan-1,3-diamine was prepared by aromatic nuclophilic substitution on 4,7-dichloroquinoline with excess of 1,3-diaminopropane in neat conditions. The amino group can be transformed to the thiazinan-4-one skeleton by the reaction of aldehyde and 3-mercaptopropionic acid in the presence of N,N-dicyclohexylcarbodiimide (DCC) whereas, DCC was utilized as a dehydrating agent to accelerate the intramolecular cyclisation, resulting in faster reaction and improved product yield. The 4-aminoquinoline derivatives of 2-substituted [1,3]thiazinan-4-ones were obtained from the N1-(7-chloroquinolin-4-yl)propan-1,3-diamine, substituted aldehyde and 3-mercaptopropionic acid in the presence of DCC in anhydrous THF at room temperature. After completion of the reaction, the desired products were obtained in excellent yields and purity. Molecular modification of synthesized derivatives was shown in Table 1.

![Figure 1](Chloroquine.png)

**Figure 1** Chloroquine.